Article
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Aug 2015
Tie J, Kinde I, Wang Y, Wong H L, Roebert J, Christie M, Tacey M, Wong R, Singh M, Karapetis C S, Desai J, Tran B, Strausberg R L, Diaz L A, Papadopoulos N, Kinzler K W, Vogelstein B, Gibbs P
Abstract excerpt
BACKGROUND: Early indicators of treatment response in metastatic colorectal cancer (mCRC) could conceivably be used to optimize treatment. We explored early changes in circulating tumor DNA (ctDNA) levels as a marker of therapeutic efficacy. PATIENTS AND METHODS: This prospective study involved 53 mCRC patients receiving standard first-line chemotherapy. Both ctDNA and CEA were assessed in plasma collected before...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.